Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

Treatment for Newly Diagnosed Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial testПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDEПодробнее

Dr. Nicholas Vogelzang Discusses Latest Advances in Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 testПодробнее

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patientsПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugsПодробнее

Dr. Vogelzang Discusses PROSPECT Trial for Prostate CancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancerПодробнее

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancerПодробнее

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancerПодробнее

Dr. Vogelzang Discusses Treatment With Radium-223 and Chemotherapy for Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Perspective on Cancer Care in the Time of COVID-19Подробнее

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosisПодробнее

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithmsПодробнее